Saxagliptin and Metformin in Fixed Combination for the Treatment of Type 2 Diabetes in Adults

Type 2 diabetes affects millions of people worldwide and significantly contributes to morbidity and mortality of those affected by it. Current guidelines recommend individualized treatment regimens following first line metformin therapy. Saxagliptin, a dipeptidyl-peptidase 4 inhibitor, provides a se...

Full description

Bibliographic Details
Main Authors:	Minze, Molly G., Klein, Mary S., Terrell, Brian T.
Format:	Online
Language:	English
Published:	Libertas Academica 2013
Online Access:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3738378/

id	pubmed-3738378
recordtype	oai_dc
spelling	pubmed-37383782013-08-21 Saxagliptin and Metformin in Fixed Combination for the Treatment of Type 2 Diabetes in Adults Minze, Molly G. Klein, Mary S. Terrell, Brian T. Review Type 2 diabetes affects millions of people worldwide and significantly contributes to morbidity and mortality of those affected by it. Current guidelines recommend individualized treatment regimens following first line metformin therapy. Saxagliptin, a dipeptidyl-peptidase 4 inhibitor, provides a secondary mechanism of action to decrease hyperglycemia when used in combination with metformin. The combination of metformin and saxagliptin has shown improvements in hemoglobin A1c and fasting plasma glucose in greater efficacy than when either agent is used alone. Adverse effects of combination therapy are similar to when these agents are used individually, and are rated as tolerable by patient satisfaction scores. Overall, the combination use of saxagliptin in addition to metformin is an attractive option for clinicians to use in the treatment of type 2 diabetes. Libertas Academica 2013-07-31 /pmc/articles/PMC3738378/ /pubmed/23966808 http://dx.doi.org/10.4137/CMED.S8510 Text en © 2013 the author(s), publisher and licensee Libertas Academica Ltd. This is an open access article published under the Creative Commons CC-BY-NC 3.0 license.
repository_type	Open Access Journal
institution_category	Foreign Institution
institution	US National Center for Biotechnology Information
building	NCBI PubMed
collection	Online Access
language	English
format	Online
author	Minze, Molly G. Klein, Mary S. Terrell, Brian T.
spellingShingle	Minze, Molly G. Klein, Mary S. Terrell, Brian T. Saxagliptin and Metformin in Fixed Combination for the Treatment of Type 2 Diabetes in Adults
author_facet	Minze, Molly G. Klein, Mary S. Terrell, Brian T.
author_sort	Minze, Molly G.
title	Saxagliptin and Metformin in Fixed Combination for the Treatment of Type 2 Diabetes in Adults
title_short	Saxagliptin and Metformin in Fixed Combination for the Treatment of Type 2 Diabetes in Adults
title_full	Saxagliptin and Metformin in Fixed Combination for the Treatment of Type 2 Diabetes in Adults
title_fullStr	Saxagliptin and Metformin in Fixed Combination for the Treatment of Type 2 Diabetes in Adults
title_full_unstemmed	Saxagliptin and Metformin in Fixed Combination for the Treatment of Type 2 Diabetes in Adults
title_sort	saxagliptin and metformin in fixed combination for the treatment of type 2 diabetes in adults
description	Type 2 diabetes affects millions of people worldwide and significantly contributes to morbidity and mortality of those affected by it. Current guidelines recommend individualized treatment regimens following first line metformin therapy. Saxagliptin, a dipeptidyl-peptidase 4 inhibitor, provides a secondary mechanism of action to decrease hyperglycemia when used in combination with metformin. The combination of metformin and saxagliptin has shown improvements in hemoglobin A1c and fasting plasma glucose in greater efficacy than when either agent is used alone. Adverse effects of combination therapy are similar to when these agents are used individually, and are rated as tolerable by patient satisfaction scores. Overall, the combination use of saxagliptin in addition to metformin is an attractive option for clinicians to use in the treatment of type 2 diabetes.
publisher	Libertas Academica
publishDate	2013
url	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3738378/
_version_	1612001838194753536

Saxagliptin and Metformin in Fixed Combination for the Treatment of Type 2 Diabetes in Adults

Similar Items